Q4 2025 CytomX Therapeutics Inc Earnings Call Transcript
Key Points
- CytomX Therapeutics Inc (CTMX) reported positive Phase 1 dose expansion data for Varseta-M in late-line colorectal cancer, showing a 32% confirmed overall response rate at 10 mg/kg and a 20% rate at 8.6 mg/kg.
- The progression-free survival (PFS) estimates have improved to 6.8 to 7.1 months, indicating enhanced efficacy over previous data.
- The company has made significant progress in managing treatment-related diarrhea, reducing Grade 3 diarrhea incidence to 10% with updated prophylactic strategies.
- Varseta-M is the first and only antibody-drug conjugate targeting EpCAM, a target previously considered undruggable due to toxicity issues.
- CytomX Therapeutics Inc (CTMX) is planning to move Varseta-M into its first registrational study, aiming for a potential multibillion-dollar market opportunity in the US by 2040.
- Despite improvements, the management of treatment-related diarrhea remains a challenge, requiring ongoing optimization of prophylactic strategies.
- The company has not yet finalized the design or size of the pivotal study, which could impact the timeline for Varseta-M's approval.
- There is uncertainty regarding the primary endpoint for the pivotal study, with overall survival (OS) likely to be required, potentially complicating the study design.
- The efficacy data is still early, particularly for the dose optimization cohorts, and further data is needed to confirm long-term benefits.
- CytomX Therapeutics Inc (CTMX) faces competition from other ADCs in development, and positioning Varseta-M as best-in-class will require continued demonstration of superior efficacy and safety.
Good morning, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics 2025 financial results and Varseta Phase 1 Dose Expansion Data Call. Please be advised that today's conference is being recorded.
I would now like to hand the conference call over to your host for today, Chris Ogden, CytomX Chief Financial Officer. Please go ahead.
Thank you. Good morning, and thank you for joining us. Before we begin, I would like to remind everyone that during this call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Earlier today, we issued a press
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
